Bharat Biotech begins phase-3 trials of Covid-19 vaccine Covaxin in India
Covaxin phase-3 trials: Volunteers who wish to participate in this trial should be adults over 18 years of age
Covaxin is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio containment facility
Bharat Biotech said it has begun the phase 3 trials of its Covid-19 vaccine candidate, Covaxin, in India. The phase-3 clinical trials will involve 26,000 participants across 22 sites in the country. The trial will be conducted in partnership with the Indian Council of Medical Research (ICMR). It is the largest clinical trial conducted for a COVID-19 vaccine in India.